Suven Life Sciences, a biopharmaceutical company, was granted patent for two of its products for their New Chemical Entities (NCEs) for the treatment of disorders associated with Neuro-degenerative diseases, according to the press release filed with the BSE.
These exclusive intellectual property of Suven will be valid till the year 2027. With these new patents, Suven now has a total of 11 granted Indian Patents on NCEs.
The products will be helpful in treatment of diseases like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD, Huntington's disease, Parkinson and Scizophrenia.
Products of these inventions may be out-licensed at various phases of clinical development.
Shares of Suven are trading at Rs 25.10 on the Bombay Stock Exchange (BSE), up 3.51 per cent from its previous close.
